Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sandoz’s Biosimilar Filing Is Culmination Of Paradigm Shift In FDA Drug Review

28 Jul 2014

• By Sue Sutter

Related Content

Biosimilars in 2014: An Interview With FDA New Drugs Head John Jenkins

04 Mar 2014

Biosimilar Podium Promotion: FDA Emphasizes Advantages Of Abbreviated Pathway

15 Oct 2012

Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows

13 Sep 2012

Related Companies

Novartis AG

Amgen, Inc.

Novartis AG

Teva Pharmaceutical Industries Ltd.

Roche Holding AG

Additional Topics

United States Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.